Published in final edited form as:

Sleep Breath. 2014 December ; 18(4): 875–883. doi:10.1007/s11325-014-0959-z.

Risk Assessment for CPAP Nonadherence in Adults with Newly-diagnosed Obstructive Sleep Apnea: Preliminary Testing of the Index for Nonadherence to PAP (I-NAP)

Amy M. Sawyer, Ph.D., R.N.^{*,1}, Tonya S. King, Ph.D.², Alexandra Hanlon, Ph.D.³, Kathy C. Richards, Ph.D., R.N.⁴, Leon Sweer, M.D.⁵, Albert Rizzo, M.D.⁶, and Terri E. Weaver, Ph.D., R.N.⁷

¹The Pennsylvania State University College of Nursing, University Park, Pennsylvania

²The Pennsylvania State University and Penn State Hershey College of Medicine, Department of Public Health Sciences, Hershey, Pennsylvania

³University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania

⁴George Mason University College of Health & Human Services, School of Nursing, Fairfax, Virginia

⁵Carlisle Regional Sleep Disorders Center, Carlisle, Pennsylvania

⁶Sleep and Lung Health Enhancement, Pulmonary Associates, P.A., Newark, Delaware

⁷University of Illinois at Chicago, College of Nursing, Chicago, Illinois

Abstract

Purpose—Identification of risk for CPAP nonadherence prior to home treatment is an opportunity to deliver targeted, adherence interventions. Study objectives included (1) test a risk screening questionnaire to prospectively identify CPAP nonadherence risk among adults with newly-diagnosed OSA; (2) reduce the questionnaire to a minimum item set that effectively identifies 1-month CPAP nonadherence; and (3) examine the diagnostic utility of the screening index.

Methods—A prospective, longitudinal study at two clinical sleep centers in the U.S. included adults with newly diagnosed OSA (n=97; AHI ≥ 5 events/hr) by polysomnogram (PSG) consecutively recruited to participate. After baseline participant and OSA characteristics were collected, a risk screening questionnaire was administered immediately following CPAP titration polysomnogram. One-month objective CPAP use was collected.

Results—Predominantly white (87%) males (55%) and females (45%) with obesity (BMI 38.3 kg/m²; SD 9.3) and severe OSA (AHI 36.8; SD 19.7) were included. One-month CPAP use was 4.25hrs/night (SD 2.35). Nineteen questionnaire items (I-NAP) reliably identified nonadherers

*Corresponding Author: Amy M. Sawyer, Ph.D., R.N., Assistant Professor, The Pennsylvania State University, School of Nursing, 129C HHD East, University Park, Pennsylvania 16802, 814-863-1020 (office), 814-863-1027 (facsimile), 215-888-2384 (mobile), ams24@psu.edu.

Conflict of Interest Disclosure:

Drs. King, Hanlon, Sweer, and Rizzo disclose no conflicts of interest.

defined at <4hr/night CPAP use (Wald $X^2[8] = 34.67$, $p < 0.0001$) with ROC AUC 0.83 (95% CI 0.74-0.91). Optimal score cut-point for the INAP screening questionnaire were determined to maximize sensitivity (87%) while maintaining specificity >60% (63%).

Conclusion—A risk screening questionnaire employed immediately after titration PSG may reliably identify CPAP nonadherers and permit the delivery of targeted interventions to prevent or reduce nonadherence. This novel approach may enhance cost-effectiveness of care and permit appropriate allocation of resources for CPAP adherence.

Keywords

Obstructive sleep apnea; Continuous positive airway pressure; Treatment compliance; Adherence; Adults

Obstructive sleep apnea (OSA) in adults is commonly treated with continuous positive airway pressure therapy (CPAP).[1] While CPAP is recognized as an efficacious treatment for OSA,[2] the effectiveness of CPAP is significantly limited by patients' use of CPAP, or adherence.[3-5] Studies that have examined the pattern of CPAP use in newly-diagnosed and treated OSA suggest that the first week of home treatment use reliably reflects long-term CPAP use patterns.[6-8] Specifically, defining consistent users as those who use CPAP 4hrs/night on 70% of nights and intermittent users as those who fail to meet this criteria, consistent users demonstrate higher rates of adherence at one month, three months, and 12 months.[6, 7] Early CPAP use as a predictor of long-term CPAP use has been replicated in other studies[5, 8] and these studies suggest that patients establish a pattern of CPAP use during the earliest period of home CPAP treatment, by day 2 to 4 of treatment,[6, 7] and remain consistent in that pattern of use for the long-term treatment period. It is therefore critical to reduce the incidence of early intermittent patterns of CPAP use that are not conducive to long-term effective treatment of OSA.

Many studies have sought to identify baseline, or pre-treatment, characteristics or factors as predictors of CPAP nonadherence.[9] OSA severity, or the apnea-hypopnea index (AHI), and subjective sleepiness are relatively consistent, yet weak, pre-treatment predictive factors that have emerged from this area of study.[3] After one week or more of home CPAP treatment, more robust predictors of CPAP adherence have emerged. These factors include spousal or immediate social support for treatment use/trouble-shooting,[10, 11] psychological factors such as treatment self-efficacy, or the belief in one's ability to use a challenging treatment,[12-15] and initial or early problems with CPAP.[10, 16] Although these factors are seemingly influential on CPAP adherence when measured at one-week, the pattern of CPAP use is likely well-established by this point in treatment. Several, relatively small, exploratory studies have identified the initial exposure to CPAP and experience with CPAP during titration polysomnogram (PSG) may be consequential to early CPAP use (i.e., adherence).[10, 16] As factors of influence at baseline, or prior to any treatment exposure, are not consistently robust predictors of short- or long-term CPAP adherence and CPAP adherence behaviors are established within the first week of home treatment, we sought to examine the first exposure to CPAP (i.e., CPAP titration polysomnogram [PSG]) as a potential opportunity to prospectively identify adult OSA patients' risk for CPAP nonadherence.

We hypothesized that a critically-timed risk screening questionnaire, employed immediately after CPAP titration PSG, will reliably identify adults with newly-diagnosed OSA who are at risk for subsequent nonadherence to CPAP at one-month. A prospective, longitudinal study was conducted to address the following specific objectives: (1) test a risk screening questionnaire to prospectively identify CPAP nonadherence risk among adults with newly-diagnosed OSA; (2) reduce the questionnaire to a minimum set of items that effectively identifies 1-month CPAP nonadherence; and (3) examine the diagnostic utility of the screening index.

METHODS

A prospective longitudinal study was conducted at two accredited clinical sleep centers in the U.S. One center was a suburban, community-based clinical center. The second was a large, academic clinical sleep center located in a suburban setting. The study was approved by the respective Institutional Review Boards (IRB).

PARTICIPANTS

Consecutive newly-diagnosed OSA patients were recruited for study participation. Inclusion criteria were: (1) newly-diagnosed OSA with apnea-hypopnea index (AHI) ≥ 5 events/hour on in-laboratory PSG, conducted and scored in accordance with standard criteria;^[17] (2) referral to CPAP titration PSG; (3) able to speak and read English. Exclusion criteria were: (1) supplemental oxygen or bilevel positive airway pressure required during titration PSG; (2) new diagnosis of psychiatric disorder within previous six months prior to study enrollment; and (3) any medical contraindication to using CPAP for treatment of OSA. All potential participants were CPAP-naïve, with no previous exposure or experience with CPAP prior to study enrollment. Initial pre-enrollment screening was conducted by a study investigator and informed consent was scheduled and completed thereafter, prior to CPAP titration PSG (n=102). The majority of participants with complete data (n=97) were from one site (n=89, 91.8%); the second site, a community-based clinical sleep center, referred and enrolled eight participants (8%) during the 18-month study period. In total, five participants were lost to follow-up (2), refused CPAP during titration PSG (2), or did not return for titration PSG (1).

PROCEDURES

After informed consent, baseline measures including self-reported demographics, medical record extraction of medical history, and OSA and physical characteristics from diagnostic PSG were collected. Participants then completed an in-laboratory, full-night CPAP titration PSG, conducted and scored according to standard procedures.^[1, 17] Prior to participants' diagnostic PSG, all patients received usual care procedures for patient education, including a pamphlet about OSA and treatment options and an educational video that provided information about OSA, PSG, treatment options, CPAP titration, and CPAP treatment. Following the titration PSG, participants completed a risk screening questionnaire, Index for Nonadherence to Positive Airway Pressure (I-NAP). Initiation of CPAP treatment was managed by the respective clinical sleep provider, which included device-specific instruction by a home medical equipment provider at the time of CPAP initiation for home

treatment, access to sleep center personnel for trouble-shooting and questions by telephone, and a scheduled follow-up visit with a sleep center provider after at least 30 days of CPAP treatment. Study participants returned to the sleep center for a scheduled research visit after one-month (i.e., 30 days) of home CPAP treatment, in all cases, prior to the scheduled clinical visit with a provider.

I-NAP was developed by the investigators based on previous work and the extant literature. The risk screening questionnaire included previously-validated instruments that were publicly-available or permission was obtained from license holder/developer. No alterations to the instruments were made for the conduct of this study. All instruments included in I-NAP have established validity and reliability for being employed in studies of OSA and CPAP-treated OSA. The instruments addressed the following evidence-based factors of influence on CPAP adherence: subjective sleepiness, daily function, health literacy, sleep-related symptoms, OSA/CPAP knowledge, perceived risks of OSA, treatment expectations, CPAP self-efficacy, and social support. The risk screening questionnaire was comprised of 111 items, inclusive of 14 sub-scales and 14 independent items (self-reported patient characteristics, physical characteristics, symptoms, and health literacy). The following measures were included in the full risk screening questionnaire:

Epworth Sleepiness Scale (ESS)—The ESS measures subjective sleepiness[18] and includes 8 items with response range of 0-3. A total score range of 0-24 indicates subjective sleepiness experienced with higher scores indicating more daytime sleepiness than lower scores.

Functional Outcomes of Sleep Questionnaire (FOSQ)—The FOSQ measures sleep-related functional impairment,[19] includes 30 items with a response range of 1-4. The total score, or global FOSQ score with a range of 5-20, based on sum of sub-scale scores, suggests overall daily functional impairment, with lower scores equating to more dysfunction. Five FOSQ subscales include activity, general productivity, social outcome, vigilance, and intimacy and sexual activity. Each FOSQ subscale has an item response range of 1-4, with lower scores equating to more dysfunction for the subscale domain. Weighted means are calculated for each subscale score and the global FOSQ score is a total score of subscale scores.

Health Literacy Screening Questionnaire (HLS)—The HLS is a general assessment of health literacy, not disease-specific.[20] The screening questionnaire is comprised of three items, each with a score range of 0-4, with 0 indicating no health literacy difficulty and 4 indicating significant difficulty for health literacy. The total score range is 0-12. Individual HLS items, dichotomized at specific cut-points, have demonstrated sensitivity and specificity for determining risk of inadequate health literacy.[20] HLS item 1 (HLS1) addresses problems with learning health-related information. HLS item 2 (HLS2) addresses self-confidence with completion of health-related forms. HLS item 3 (HLS3) addresses problems with reading.[20] To our knowledge, no previous studies have examined health literacy as an influential factor on CPAP adherence. Therefore, the total HLS score and individual items for inadequate health literacy risk were examined.

Sleep Symptoms—A single item measured sleep symptoms for which participants sought care at a sleep center. Respondents selected all sleep-specific symptoms that were applicable from a response set of five options.

Social Cognitive Theory Questionnaire in OSA (SCT)—The questionnaire includes 4 subscales: knowledge of OSA and CPAP (12 items), outcome expectancies with treatment (4 items), treatment-specific self-efficacy (5 items), and social support (9 items).[13] Each subscale score range is 1-5 with exception of the knowledge subscale, which is scored percent of correct responses based on true/false responses.

Self-efficacy Measure in Sleep Apnea (SEMSA)—The SEMSA is a disease-specific instrument that includes three subscales that measure risk perception (8 items), outcome expectancies (9 items), and treatment-specific self-efficacy (9 items).[21] The response range for each item is 1-4. A weighted mean is calculated for each subscale; no total score is calculated for the SEMSA.

STUDY VARIABLES, OUTCOMES AND MEASURES

Participant Characteristics—A questionnaire eliciting demographic information and presenting symptoms was completed by all study participants at enrollment. Weight and height for calculation of body mass index (BMI) were extracted from the diagnostic PSG.

Diagnostic PSG—Diagnostic PSG data was collected at study enrollment. Studies were scored based on standard criteria[17] employing the alternative hypopnea definition, a 50% decrement in nasal pressure of 10 seconds or more, and 3% desaturation.[17] Variables included AHI, oxygen nadir in non-REM, and total sleep time 90% (minutes and %).

Index for Nonadherence to PAP (I-NAP)—Risk screening questionnaire was administered on a single occasion, immediately after CPAP titration in the laboratory. The questionnaire, as described above, was completed by participants, on average, in 15 minutes. Only instrument sub-scales (14), total instrument scores (2), and 14 individual descriptive items were statistically examined. I-NAP is assessed at a 5th grade reading level.

CPAP Use—Objective one month CPAP use was collected using the internal microprocessor on standard CPAP devices. Use was recorded as mean hours/night at effective pressure > 20 minutes.

ANALYSIS

All variables, including screening questionnaire sub-scale scores and scale total scores, if appropriate, were summarized using standard descriptive statistics. All potential predictors with *a priori*-defined level of CPAP nonadherence < 4hrs mean CPAP use (clinical benchmark) were entered as predictors in corresponding logistic regression models. CPAP use was categorized as nonadherent at < 4 hrs ([n=38; 39.2%] or adherent at 4hrs (n=59; 60.1%).

Terms were removed from the model using a backward elimination procedure, deleting factors wherein removal caused an insignificant change in the predictive ability of the model

as determined by Wald statistic. Variables included in the model were restricted such that there were at least 10 cases of nonadherence/adherence for each variable in order to minimize Type I errors in variable selection. A final logistic regression model with receiver operating characteristic curve (ROC) was produced for CPAP adherence level of < 4hrs use per night. A regression equation was derived from the final logistic regression model to produce a composite score which was evaluated as a diagnostic test. An additional logistic regression model was then fit containing only the composite score as a predictor, and a corresponding ROC curve was produced. The area under the curve (AUC) of this ROC curve was compared to the nominal value of 0.5 of an uninformative model within the logistic regression procedure. In addition, a simplified composite score was estimated from the regression coefficients rounded to one decimal place. The corresponding ROC curve from the simplified composite score was compared to that of the original composite score to determine whether the simplified version could be applied in practice. The comparison of the AUC of the two ROC curves was also performed within the logistic regression procedure.

Multiple test cutoff points were then assessed for the composite score, and each of these cutoff points was associated with a true positive rate (TPR) and false positive rate (FPR) based on actual outcome. ROC curves graphically describe the relationship between choice of cutoff and the associated test characteristics. The AUC associated with the ROC curve measures the ability to discriminate between non-adherers and adherers. The ROC curve and respective sensitivity, specificity, TPR and FPR were used to choose the optimal cutoff point for each test.

Because the division of the data into training and validation data sets would have resulted in an unacceptably small training data set, cross-validation was used, providing an unbiased assessment of the model without reducing the training data set. Cross-validation was performed within the logistic regression model by ignoring one observation at a time and using the remaining observations to compute the predicted probability for the ignored observation. The cross-validated predicted probabilities were then used in an ROC analysis.

To determine the required sample size for the study based on having adequate statistical power to determine that a predictive model for non-adherence at 1 month was more sensitive than chance, an AUC of at least 0.70 was considered significant. Based on prior work, we assumed a 50% non-adherence rate, 80% power and $\alpha=0.05$. In order to determine if one model was at least 25% more accurate than another with ROC area under the curve of 0.70, a sample size of 82 subjects was required. Our previous experience enrolling similar participants in studies of CPAP adherence guided our application of a 20% attrition rate, resulting in 102 enrolled subjects to achieve the required sample size of $n=82$ with complete data.

RESULTS

SAMPLE DESCRIPTION

The sample ($n=97$) included predominantly males (54.7%) and females (45.4%), middle-aged ($49.5 \text{ years} \pm 11.6$), with severe OSA (AHI $36.7 \text{ events/hr} \pm 19.7$; Table 1).

Participants were married (69.1%), educated at high school level or college (96.9%), employed part-time or full-time (74.2%), and predominantly self-identified their race as white (86.6%) or black (6.2%). The majority of the sample was referred for sleep evaluation by a family physician/primary care provider (66%), pulmonary specialist (13.4%), or cardiologist (5.2%). Mean one month CPAP use was 4.25hr/night (SD 2.35).

I-NAP RISK ASSESSMENT QUESTIONNAIRE

The risk assessment for nonadherence to CPAP questionnaire included Epworth Sleepiness Scale total score, Functional Outcomes of Sleep Questionnaire total score and five sub-scale scores, three sub-scale scores for the Self-efficacy Measure in Sleep Apnea, Health Literacy Screening questionnaire total score and three individual items, and four sub-scale scores for Social Cognitive Theory questionnaire for OSA. Individual instrument total scores and sub-scores are reported in Table 2.

ITEM SELECTION FOR I-NAP

Bivariate associations of participant characteristics and risk assessment questionnaire total scores and/or subscale scores were examined with 1 month CPAP use. Mean CPAP use was dichotomized at < 4hrs/night. Variance inflation factors (VIF) were examined to remove variables based on collinearity for the CPAP use model and criteria for 10 cases per adherence category were examined. These diagnostic procedures resulted in the removal of FOSQ total score and HLS total score from the model (collinearity); rotating shift was also removed from the model (case number criteria). A logistic regression model for < 4hrs/night CPAP use was reduced by backward stepwise selection and resulted in eight (8) significant sub-scale scores or characteristic variables remaining in the final < 4hr/night CPAP use I-NAP model (Table 3).

I-NAP < 4 H_{RS}/NIGHT CPAP U_{SE}

The final I-NAP predictors for < 4hrs/night of CPAP use included SEMSA outcome expectancy, SCT self-efficacy, HLS1, body mass index (BMI), marital status, sleepiness as a presenting symptom with the referent group being absence of symptom, restlessness during sleep as a presenting symptom with the referent group being absence of symptom, and gender, with male as the referent group. The final model, inclusive of the eight variables, is well-fit (Likelihood ratio test [LR], $X^2[8] = 34.67$, $p < 0.0001$).

I-NAP < 4 H_{RS}/NIGHT CPAP U_{SE} S_{ENSITIVITY} AND S_{PECIFICITY}

The ROC curve was examined for predictive utility of the reduced I-NAP model for the CPAP adherence cut-point of < 4hrs/night in the study sample. With an area under the curve (AUC) of 0.83 (95% CI 0.74-0.91), the I-NAP demonstrates good diagnostic utility in terms of differentiating those likely to be nonadherent at < 4hrs/night after 30 days of CPAP treatment. A Gamma value of 0.66 for the final ROC suggests 66% fewer errors are made employing the model to identify “non-adherers” at the 4hr cut-point than by chance alone. To examine sensitivity and specificity, the I-NAP regression equation for the 4hr cut-point model was produced:

$$\text{INAP-4} = -0.8 * \text{meanSEMSAO} - 0.6 * \text{meanSCTSE} - 0.6 * \text{HLS1} + 0.05 * \text{BMI} - 1.1 * \text{married01} - 1.5 * \text{sleepiness} + 1.1 * \text{restless sleep} + 0.7 * \text{female},$$

where meanSEMSAO is the mean SEMSA outcome expectancy sub-scale score, meanSCTSE is the mean Social Cognitive Theory in Sleep Apnea Self-efficacy subscale score, HLS1 is the Health Literacy Screening question 1 score, BMI is the body mass index, married01 is a binary variable (unmarried = 0; married = 1), sleepiness is a binary variable (sleepiness as presenting symptom, absent = 0; present = 1), restless sleep is a binary variable (restlessness during sleep as presenting symptom, absent = 0; present = 1), and female is a binary variable (male = 0; female = 1). I-NAP composite score is well-fit ($X^2[1]=20.25$, $p<0.0001$) with an OR of 2.75 (95% CI 1.77-4.26). Employing only the I-NAP composite score, a second receiver operating characteristic curve demonstrated AUC 0.83 (95% CI 0.74-0.91; $p<0.001$ vs. noninformative model). The estimation of the cumulative score with coefficients rounded to one decimal place was not significantly different from the full expression of the predicted probabilities ($p=0.71$), which supports the use of the cumulative score expression shown above. The cross-validation procedure produced an ROC curve with a similar AUC of 0.81 (95% CI 0.72-0.90). As this is a diagnostic screening instrument, an optimal cut-point that maximized sensitivity while preserving specificity was desired, which resulted in a cut-point for I-NAP -4.8 (Figure 1). At this I-NAP optimal cut-point for identifying adults with risk of CPAP adherence < 4 hrs/night after 30 days of treatment, sensitivity was 87% and specificity was 63% (Table 4).

DISCUSSION

Our prospective, longitudinal study sought to test, reduce, and examine the predictive utility of a risk screening questionnaire, employed after first exposure to CPAP among CPAP-naïve adults with OSA, to identify subsequent risk of CPAP nonadherence at 1 month. To our knowledge, no previous published studies have prospectively tested a simplistic mechanism, such as a screening questionnaire, to identify newly-diagnosed OSA adults who are likely to be nonadherent to subsequent CPAP treatment. I-NAP screening questionnaire for CPAP use < 4 hrs/night reliably identified subjects in our study at risk for CPAP nonadherence at 1 month and has good sensitivity (i.e., > 0.80). I-NAP was reduced to eight measured domains, including outcome expectancies, treatment self-efficacy, health literacy, BMI, marital status, symptoms on presentation, and gender, consisting of a total of 19 individual questionnaire items (Table 5).

Screening tests or instruments are commonly used when (1) the gold standard test or instrument is invasive, expensive, or generally inaccessible; (2) assessment of risk is cost-effective and/or reduces morbidity and/or mortality; and/or (3) when prevalence of the condition is common and treatment is available.[22] As nonadherence to CPAP is estimated at 50%[3] and contributes to persistent poor health and functional outcomes in OSA[4], a screening instrument for nonadherence to CPAP is a reasonable approach to improve cost-effective OSA care and lessen morbidity associated with nonadherence. It is well-established that CPAP nonadherence patterns develop in the earliest phase of CPAP treatment and these usage patterns are reflective of long-term adherence outcomes.[6-8] For this reason, it is imperative to identify CPAP nonadherence at the earliest possible point in

the course of treatment. Testing of the I-NAP screening questionnaire immediately after first exposure to CPAP, i.e., CPAP titration, supports identification of nonadherers before these non-conductive patterns are established and is also consistent with evidence that suggests early CPAP experiences are influential on initial CPAP acceptance and early patterns of use. [8, 16, 23] As the purpose of the I-NAP is to prospectively identify adults with risk of subsequent nonadherence to CPAP, sensitivity, or true positive case identification, was prioritized when determining the I-NAP cut-off point with careful consideration of maintaining a moderate level of specificity, or true negative case identification, greater than 60%. A negative predictive value >85% was identified for the optimal screening cut-point, suggesting that the risk screening questionnaire effectively identifies cases that are true negatives based on objective CPAP use at one month.

Similar to our own findings, Balachandran and colleagues[24] retrospectively examined the predictive utility of a CPAP perception survey as a brief screening tool to predict CPAP nonadherence at one month. The survey procedure was initially designed as a quality improvement project. Assessing similar domains as the I-NAP, with several items addressing CPAP treatment self-efficacy and outcome expectancies, and collecting survey responses immediately after CPAP titration PSG, Balachandran and colleagues' study[24] and our own study provide preliminary evidence that risk assessment surveys for CPAP nonadherence are a valid and clinically feasible approach to determining which patients require CPAP adherence intervention. Though prior reported research has applied and tested a similar strategy of risk assessment in a retrospective fashion and successfully identified adherers,[25] our own study and Balachandran's study importantly differentiated both adherers and nonadherers.

This preliminary study is not without limitations. The clinical sample characteristics included predominantly high school or higher educated subjects, minimal representation of diversity in terms of race and ethnicity, and a relatively low representation of absolute nonadherers (i.e., 0hrs use). These limitations may have implications on the overall predictive validity of I-NAP in general sleep clinical settings. Future testing of the I-NAP in a larger sample and across multiple sites to increase sample heterogeneity is needed. For the purpose of validating the I-NAP, a second validation sample or sub-sample from the full sample would ideally have been included in the initial preliminary testing. We conducted a *a priori* power analysis that suggested the retained sample size, n=97, was adequate to test for statistically significant differences in ROC-determined I-NAP score cut-points. We also conducted a cross-validation procedure to assess the model fit in order that the sample size would not be reduced for validation purposes. As this study was designed as a preliminary study to develop and test a simplistic risk screening instrument, additional predictive utility testing is recommended. Such studies will necessarily include a validation sample to better delineate the clinical utility of the I-NAP in the care of CPAP-treated OSA.

Several studies have examined the cost-effectiveness of CPAP treatment for OSA in adults. [26-28] When quality of life, costs of therapy, and motor vehicle crashes were considered, CPAP was a highly efficient use of healthcare resources; CPAP use less than 4hrs per night on 70% of nights, modeled as no CPAP, was not cost-effective. Based on the principles of resource allocation and cost effectiveness, combined with our current understanding of the

efficacy of CPAP in OSA, risk assessment for CPAP nonadherence is a simplistic, economical and low-burden approach to potentially contribute to improved outcomes and resource utilization in the OSA population. Furthermore, as is recommended by the current clinical guidelines for diagnosis, treatment and long-term management of OSA in adults[29], implementation of an “early compliance program” may be facilitated by risk screening of OSA patients after CPAP titration PSG, at the earliest phase of treatment exposure, to permit targeted delivery of compliance programs to those adults identified as “at risk” for CPAP nonadherence.

Building upon a relatively large body of evidence addressing CPAP nonadherence and influential factors on short-term CPAP adherence outcomes, we developed a risk assessment for CPAP nonadherence in adults with OSA. I-NAP, identifying CPAP use < 4hrs/night at 1 month, includes a minimum set of items that address multiple domains of recognized influence on CPAP adherence and is both simplistic and consistent in delivery with standardized care intervals at sleep centers. By incorporating a validated risk assessment of nonadherence to CPAP prior to treatment initiation, the chronic care of CPAP-treated OSA in adults may be improved. Specifically, clinical decision-making and resource allocation may be enhanced by early identification of adults most likely to require targeted or personalized interventions to improve CPAP adherence.

Acknowledgments

The project described was supported by Grant Number R00NR011173 and K99NR011173 from the National Institute of Nursing Research/National Institutes of Health. The authors acknowledge the sleep center staff members and providers who supported research recruitment, enrollment, and protocol procedures at the respective centers and early consultation with Greg Maislin, Biomedical Statistical Consulting and Judy A. Shea, PhD, University of Pennsylvania.

Dr. Sawyer has received funding from National Institutes of Health/NINR, American Nurses Foundation and Sigma Theta Tau International, and has received honoraria as an educational speaker for the American Academy of Sleep Medicine. Dr. Weaver discloses the following: Research equipment support from Philips Respironics, Inc.; Grant support from TEVA, Inc. (2008-13); FOSQ License Agreements with Nova Som, GlaxoSmithKline, Philips Respironics, Cephalon, Inc., and Nova Nordisk; and serves on the Board of Directors for ViMedicus, Inc. Dr. Weaver also has received research support from National Institutes of Health. Dr. Richards has received research support from Philips Respironics, Inc., National Institutes of Health, and the Department of Veterans Affairs.

References

1. Kushida CA, et al. Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. *Sleep*. 2006; 29:375–80. [PubMed: 16553024]
2. Gay P, et al. Evaluation of positive airway pressure treatment for sleep related breathing disorders in adults. *Sleep*. 2006; 29:381–401. [PubMed: 16553025]
3. Sawyer AM, et al. A systematic review of CPAP adherence across age groups: Clinical and empiric insights for developing CPAP adherence interventions. *Sleep Med Rev*. 2011; 15:343–56. [PubMed: 21652236]
4. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: The challenge to effective treatment. *Proc Am Thorac Soc*. 2008; 5:173–178. [PubMed: 18250209]
5. McArdle N, et al. Long-term use of CPAP therapy for sleep apnea/hypopnea syndrome. *Am J Resp Crit Care Med*. 1999; 159:1108–1114. [PubMed: 10194153]
6. Weaver TE, et al. Night-to-night variability in CPAP use over first three months of treatment. *Sleep*. 1997; 20:278–283. [PubMed: 9231953]

7. Aloia MS, et al. How early in treatment is PAP adherence established? Revisiting night-to-night variability. *Behav Sleep Med.* 2007; 5:229–240. [PubMed: 17680733]
8. Budhiraja R, et al. Early CPAP use identifies subsequent adherence to CPAP therapy. *Sleep.* 2007; 30:320–324. [PubMed: 17425228]
9. Crawford MR, et al. Integrating psychology and medicine in CPAP adherence - New concepts? *Sleep Med Rev.* 2013 <http://dx.doi.org/10.1016/j.smrv.2013.03.002>.
10. Lewis K, et al. Early predictors of CPAP use for the treatment of obstructive sleep apnea. *Sleep.* 2004; 27:134–138. [PubMed: 14998250]
11. Baron K, et al. Spousal involvement in CPAP adherence among patients with obstructive sleep apnea. *Sleep Breath.* 2011; 15:525–34. [PubMed: 20549372]
12. Sawyer A, et al. Do cognitive perceptions influence CPAP use? *Patient Educ Couns.* 2011; 85:85–91. [PubMed: 21071166]
13. Stepnowsky CJ, et al. Psychologic correlates of compliance with continuous positive airway pressure. *Sleep.* 2002; 25:758–762. [PubMed: 12405612]
14. Baron K, et al. Self-efficacy contributes to individual differences in subjective improvements using CPAP. *Sleep Breath.* 2011; 15:599–606. [PubMed: 20844971]
15. Aloia MS, et al. Predicting treatment adherence in obstructive sleep apnea using principles of behavior change. *J Clin Sleep Med.* 2005; 1:346–353. [PubMed: 17564399]
16. Drake CL, et al. Sleep during titration predicts continuous positive airway pressure compliance. *Sleep.* 2003; 26:308–311. [PubMed: 12749550]
17. Iber, C., et al. *The AASM Manual for the Scoring of Sleep and Associated Events.* American Academy of Sleep Medicine; Westchester, IL: 2007.
18. Johns MW. Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale. *Chest.* 1993; 103:30–36. [PubMed: 8417909]
19. Weaver TE, et al. An instrument to measure functional status outcomes for disorders of excessive sleepiness. *Sleep.* 1997; 20:835–843. [PubMed: 9415942]
20. Chew LD, Bradley KA, Boyko EJ. Brief questions to identify patients with inadequate health literacy. *Fam Med.* 2004; 36:588–94. [PubMed: 15343421]
21. Weaver TE, et al. Self-efficacy in sleep apnea: Instrument development and patient perceptions of obstructive sleep apnea risk, treatment benefit, and volition to use continuous positive airway pressure. *Sleep.* 2003; 26:727–732. [PubMed: 14572127]
22. Wilson, JMG.; Junger, G. *Public Health Papers.* World Health Organization; Geneva: 1968. Principles and Practice of Screening for Disease.
23. Sawyer AM, et al. Differences in perceptions of the diagnosis and treatment of obstructive sleep apnea and continuous positive airway pressure therapy among adherers and nonadherers. *Qual Health Res.* 2010; 20:873–92. [PubMed: 20354236]
24. Balachandran JS, et al. A brief survey of patients' first impression after CPAP titration predicts future CPAP adherence: A pilot study. *J Clin Sleep Med.* 2013; 9:199–205. [PubMed: 23493772]
25. Ghosh D, Allgar V, Elliott MW. Identifying poor compliance with CPAP in obstructive sleep apnea: A simple prediction equation using data after a two week trial. *Respir Med.* 2013; 107:936–42. [PubMed: 23146555]
26. Tan MCY, et al. Cost-effectiveness of continuous positive airway pressure therapy in patients with obstructive sleep apnea-hypopnea in British Columbia. *Can Respir J.* 2008; 15:159–65. [PubMed: 18437259]
27. Guest JF, et al. Cost-effectiveness of using continuous positive airway pressure in the treatment of severe obstructive sleep apnea/hypopnoea syndrome in the UK. *Thorax.* 2008; 63:860–65. [PubMed: 18408048]
28. Ayas NT, et al. Cost-effectiveness of continuous positive airway pressure therapy for moderate to severe obstructive sleep apnea/hypopnea. *Arch Int Med.* 2006; 166:977–984. [PubMed: 16682570]
29. Epstein LJ, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med.* 2009; 5:263–76. [PubMed: 19960649]

Figure 1. Predictive Utility of the I-NAP Composite Score for < 4hrs/night CPAP Use (n=97)

ROC – Receiver Operating Characteristic curve

AUC=0.83 (95% CI 0.74-0.91); Somers' D = 0.65

Table 1

Sample Description

Characteristic	Total Sample (n=97) Frequency (n[%]) or Mean ($\pm$ SD)
Male	53 (54.6%)
Age (yrs)	49.5 (11.6)
Race	
White	84 (86.6%)
Black or African American	6 (6.2%)
Native Hawaiian/Other Pacific Islander	2 (2.1%)
Asian	2 (2.1%)
American Indian/Alaska Native	3 (3.1%)
Ethnicity	
Hispanic or Latino	8 (8.3%)
Not Hispanic or Latino	89 (91.8%)
Married	67 (69.1%)
Education	
High School	31 (32%)
Some College or more	63 (65%)
Employment	
Working Full-time	63 (65%)
Working Part-time	9 (9.3%)
Homekeeper	3 (3.1%)
Unemployed	6 (6.2%)
Student	3 (3.1%)
Retired	13 (13.4%)
Rotating Shift Work	6 (6.2%)
Night Shift Work (consistent shift)	3 (3.1%)
Referral Source	
Family or Primary Care Provider	64 (66%)
Pulmonary Specialist	13 (13.4%)
Cardiology	5 (5.2%)
Neurology	4 (4.1%)
Psychiatry	1 (1%)
Family member or friend	5 (5.2%)
Self	5 (5.2%)
Body Mass Index (kg/m ²)	38.3 (9.3)
Apnea Hypopnea Index (events/hour)	36.8 (19.7)
Mild (5-15 events/hour)	10 (10.3%)
Moderate (>15-30 events/hour)	29 (29.9%)
Severe (>30 events/hour)	58 (59.8%)

Characteristic	Total Sample (n=97) Frequency (n[%]) or Mean ($\pm$ SD)
NR Oxyhemoglobin Saturation Nadir	81.0 (6.8)
Total Sleep Time (TST) Oxyhemoglobin Saturation 90% (mean % TST)	14.9% (17.4)
CPAP Use at 30 days (mean hours/night)	4.25 (2.35)
4 hr cut-point (nonadherers)	38 (39.2%)

NR, NonREM; CPAP, Continuous Positive Airway Pressure

Table 2

Risk Assessment Scores by Domain Total Scores and/or Sub-scale Scores (n=97)

INAP Domain	Assessment Scored	Mean (SD) or n (%)	Score Range
Epworth Sleepiness Scale (ESS)	Total Score	10.6 (4.84)	0.0 – 21.0
Functional Outcomes of Sleep Questionnaire (FOSQ)	Total Score 5 Subscale Scores Activity General Productivity Social Outcome Vigilance Intimacy and Sexual Activity	15.7 (2.8) 2.9 (0.7) 3.3 (0.5) 3.4 (0.6) 3.0 (0.7) 3.2 (0.8)	7.9 – 19.9 1.2 – 3.9 1.7 – 4.0 1.5 – 4.0 1.1 – 4.0 1.0 – 4.0
Self-efficacy Measure in Sleep Apnea (SEMSA)	3 Subscale Scores Risk Perception Outcome Expectancies Treatment Self-efficacy	2.7 (0.6) 3.2 (0.6) 3.0 (0.6)	1.1 – 3.9 1.6 – 4.0 1.0 – 4.0
Health Literacy Screening Questionnaire (HLS)	Total Score *3 Item Scores HLS1 (+) screen score (n[%]) HLS2 (+) screen score (n[%]) HLS3 (+) screen score (n[%])	2.3 (2.2) 50 (51.6%) 24 (24.7%) 18 (18.6%)	0.0 – 9.0
Social Cognitive Theory Questionnaire in OSA	4 Subscale Scores Self-efficacy Outcome expectancy Social Support ‡OSA & CPAP Knowledge (% correct response)	4.2 (0.8) 4.4 (0.7) 4.5 (0.7) 93.1 (8.5)	1.0 – 5.0 2.3 – 5.0 2.4 – 5.0 58.3 – 100.0

* Health Literacy Screening Questionnaire items, HLS1, HLS2, HLS3, frequency (n[%]) for positive screening for inadequate health literacy

‡ Social Cognitive Theory Questionnaire in OSA knowledge domain scored for % of correct responses; mean sub-scale score and standard deviation (SD) reported

Table 3Logistic Regression Model for <4hrs/night CPAP Use I-NAP[‡] (n=97)

Variable	B Coefficient	SE	Wald Chi-square [df=1]	p value*	OR (95% CI)
Intercept	3.80	2.13	3.20	0.07	NA
[‡] SEMSA Outcome Expectancy	-0.80	0.50	2.57	0.11	0.45 (0.17-1.20)
[‡] SCT Self-efficacy	-0.59	0.37	2.52	0.11	0.55 (0.27-1.15)
[‡] HLS1	-0.59	0.33	3.17	0.08	0.55 (0.29-1.06)
BMI	0.05	0.03	2.69	0.10	1.05 (1.00-1.12)
Marital Status (Married)	-1.15	0.56	4.25	0.04	0.32 (0.11-0.95)
Sleepiness as presenting symptom	-1.52	0.62	5.95	0.01	0.22 (0.07-0.74)
Restlessness in sleep as presenting symptom	1.07	0.56	3.69	0.05	2.92 (0.98-8.69)
Gender (Female)	0.74	0.55	1.78	0.18	2.09 (0.71-6.16)

Variables that did not meet significance level included: HLS3 (p=0.80), HLS2 (p=0.49), ESS (p=0.67), FOSQ Productivity (p=0.22), FOSQ Activity (p=0.23), FOSQ Vigilance (p=0.41), FOSQ Social Outcome (p=0.75), FOSQ Intimacy & Sexual Activity (p=0.69); SEMSA Risk Perception (p=0.84), SEMSA Self-efficacy (p=0.79), SCT Outcome Expectancies (p=0.93), SCT Knowledge (p=0.40); SCT Social Support (p=0.23). Variables excluded from analysis due to collinearity included Total FOSQ score and Total HLS; Shift work excluded due to insufficient number of cases per adherence group.

[‡] Likelihood Ratio Test $\chi^2[8]=34.67$, $p<0.0001$

[‡] SEMSA - Self-efficacy Measure in Sleep Apnea; SCT - Social Cognitive Theory Questionnaire in Sleep Apnea; HLS - Health Literacy Screening Questionnaire; BMI - Body Mass Index; SCT - Social Cognitive Theory Questionnaire in Sleep Apnea; FOSQ - Functional Outcomes of Sleep Questionnaire; SE-Standard Error; OR=Odds Ratio.

* p value to remain in the model defined at $p<0.20$

Table 4

I-NAP Cut-Point -4.8 Predictive Utility (n=97)

		CPAP Adherence < 4hrs/night	
		Yes	No
I-NAP4 Screening Index Cut-Point -4.8 [†]	Yes	33 True +	22 False +
	No	5 False -	37 True-

[†] Sensitivity = 87%; Specificity = 63%; PPV = 60%; NPV = 88%

Table 5

INAP Items and Sub-scales

Item or Sub-scale	Format & Number of Items Included	Source
Self-efficacy Measure in Sleep Apnea (SEMSA) – Outcome Expectancies sub-scale	4-point Likert scale; 9 items	Available with permission from author [*]
Social Cognitive Theory Questionnaire in Sleep Apnea – Self-efficacy sub-scale	5-point Likert scale; 5 items	Publicly available [†]
Health Literacy Questionnaire <ul style="list-style-type: none"> How often do you have problems learning about your medical condition because of difficulty understanding written information? 	5-point Likert scale; 1 item	Publicly available [‡]
BMI	1 item	-
Marital Status <ul style="list-style-type: none"> Married Not married 	1 item	-
Presenting symptoms for seeking care at sleep center <ul style="list-style-type: none"> Restless sleep Snoring Breathing stops in sleep Sleepiness during day Other 	1 item	-
Gender <ul style="list-style-type: none"> Male Female 	1 item	-

^{*} Weaver TE, Maislin G, Dinges DF, et al. Self-efficacy in sleep apnea: Instrument development and patient perceptions of obstructive sleep apnea risk, treatment benefit, and volition to use continuous positive airway pressure. *Sleep* 2003;26:727-32.

[†] Stepnowsky CJ, Marler MR, Ancoli-Israel S. Determinants of nasal CPAP compliance. *Sleep Medicine* 2002;3: 239-47.

[‡] Chew LD, Bradley KA, Boyko EJ. Brief questions to identify patients with inadequate health literacy. *Family Medicine* 2004;36: 588-94.